ArticleJournal of virology1999
Inhibitory mechanism of the CXCR4 antagonist T22 against human immunodeficiency virus type 1 infection.
Article in Journal of virology, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 88 citations in OpenAlex.
- Advances in Nanotechnology for Lymphoma Treatment: Targeted Delivery, Immunomodulation, and TME-Responsive Therapy Strategies.International journal of nanomedicine · 2026Review
- Structural Stabilization of Clinically Oriented Oligomeric Proteins During their Transit through Synthetic Secretory Amyloids.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Cancer immunogenic cell death via pyroptosis with CXCR4-targeted nanotoxins in hepatocellular carcinoma.Frontiers in bioengineering and biotechnology · 2024Article
- CXC chemokine receptor 4 (CXCR4) blockade in cancer treatment.Journal of cancer research and clinical oncology · 2023Review
- Oligonucleotides Carrying Nucleoside Antimetabolites as Potential Prodrugs.Current medicinal chemistry · 2023Review
- Chemokine-Decorated Nanoparticles Target Specific Subpopulations of Primary Blood Mononuclear Leukocytes.Nanomaterials (Basel, Switzerland) · 2022Article
- Self-assembling protein nanocarrier for selective delivery of cytotoxic polypeptides to CXCR4Acta pharmaceutica Sinica. B · 2022Article
- Article
- CXCL12-PLGA/Pluronic Nanoparticle Internalization Abrogates CXCR4-Mediated Cell Migration.Nanomaterials (Basel, Switzerland) · 2020Article
- Fluorescent Dye Labeling Changes the Biodistribution of Tumor-Targeted Nanoparticles.Pharmaceutics · 2020Article
- Efficient bioactive oligonucleotide-protein conjugation for cell-targeted cancer therapy.ChemistryOpen · 2019Article
- Pathogenic Viruses Commonly Present in the Oral Cavity and Relevant Antiviral Compounds Derived from Natural Products.Medicines (Basel, Switzerland) · 2018Review
- Bacterial mimetics of endocrine secretory granules as immobilized in vivo depots for functional protein drugs.Scientific reports · 2016Article
- Anti-HIV drug development through computational methods.The AAPS journal · 2014Review
- Multifaceted mechanisms of HIV-1 entry inhibition by human α-defensin.The Journal of biological chemistry · 2012Article
- Galectin-1-specific inhibitors as a new class of compounds to treat HIV-1 infection.Antimicrobial agents and chemotherapy · 2012Article
- Intracellular CXCR4⁺ cell targeting with T22-empowered protein-only nanoparticles.International journal of nanomedicine · 2012Article
- Mechanisms and modifications of naturally occurring host defense peptides for anti-HIV microbicide development.Current HIV research · 2012Review
- The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100.Antimicrobial agents and chemotherapy · 2009Article
- Staphylococcal superantigen-like 10 inhibits CXCL12-induced human tumor cell migration.Neoplasia (New York, N.Y.) · 2009Article
Corrections and comments
- Erratum issued
Authors and funding
15 authors at 1 institution in 1 country.
Funding
Abstract
We recently reported that a cationic peptide, T22 ([Tyr(5,12), Lys(7)]-polyphemusin II), specifically inhibits human immunodeficiency virus type 1 (HIV-1) infection mediated by CXCR4 (T. Murakami et al., J. Exp. Med. 186:1389-1393, 1997). Here we demonstrate that T22 effectively inhibits replication of T-tropic HIV-1, including primary isolates, but not of non-T-tropic strains. By using a panel of chimeric viruses between T- and M-tropic HIV-1 strains, viral determinants for T22 susceptibility were mapped to the V3 loop region of gp120. T22 bound to CXCR4 and interfered with stromal-cell-derived factor-1alpha-CXCR4 interactions in a competitive manner. Blocking of anti-CXCR4 monoclonal antibodies by T22 suggested that the peptide interacts with the N terminus and two of the extracellular loops of CXCR4. Furthermore, the inhibition of cell-cell fusion in cells expressing CXCR4/CXCR2 chimeric receptors suggested that determinants for sensitivity of CXCR4 to T22 include the three extracellular loops of the coreceptor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.